Inno Medicine Completes Nearly RMB 800 Million Series D Financing to Accelerate Global Multi-Center Clinical Development of Core Pipelines

BEIJING and Shanghai, September 8, 2026 — Beijing Inno Medicine Co., Ltd. (“Inno Medicine” or the “Company”) today announced the completion of its Series D financing round, raising nearly RMB 800 million. The round was led by Yuanbio Venture Capital, with participation from co-investors including the Beijing Medical and Healthcare Industry Investment Fund, the Beijing Advanced Manufacturing and Intelligent Equipment Industry Investment Fund and its co-manager Cornerstone Capital, Chengtong Science & Technology Innovation Fund Management, Genharmony Capital, Gaorong Ventures, Northern Light Venture Capital, and Zhongqi Capital, alongside follow-on investments from existing shareholders Renhe Capital and Chunjia Capital. The proceeds will be primarily used to advance international multi-center clinical trials for the Company’s core pipeline products, further accelerating their global clinical development and commercialization.

Inno Medicine’s core pipelines have now entered critical stages of clinical development. Leveraging its proprietary Active Targeting Liposome (ATL) delivery technology platform, the Company has achieved significant progress across cardiovascular and central nervous system (CNS) oncology therapeutics:

The Company’s lead pipeline candidate is the world’s first active targeted therapy designed to reverse atherosclerotic plaques. By selectively accumulating in atherosclerotic plaques, it exerts dual anti-inflammatory and cholesterol efflux-promoting effects, facilitating the transport of cholesterol from within plaques into the bloodstream through reverse cholesterol transport. By acting directly on atherosclerotic plaques, it is designed to reduce plaque volume and promote plaque stabilization, with the potential to deliver a new breakthrough in the treatment of cardiovascular disease worldwide. The drug’s Phase 2b international multi-center pivotal registration trial (PURIFY-TIMI 81) has entered the patient enrollment stage, with study centers in China, Australia, and the United States already being activated, and the Canadian study center expected to be activated shortly.

Another glioma-targeted innovative drug candidate developed on the Company’s drug delivery platform is designed to efficiently cross the blood-brain barrier and selectively accumulate in glioma tissue, enabling efficient targeted drug delivery while significantly reducing systemic toxicity. In addition to directly killing tumor cells, the drug can induce immunogenic cell death (ICD), activating the immune system to generate a durable and synergistic anti-tumor response. The drug recently received Fast Track Designation and IND approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with glioma, including glioblastoma. Previously, the drug received Orphan Drug Designation (ODD) from the FDA in November 2023.

Dr. Qian Ma, Founder, Chairwoman, and CEO of Inno Medicine, stated: “We are deeply grateful to our new investors for their trust and support, as well as to our long-standing shareholders for their continued partnership. The successful completion of this Series D financing reflects strong recognition from the capital markets of Inno Medicine’s R&D capabilities, the clinical value of our core pipelines, and our potential for global growth. Moving forward, we will continue to leverage the high technical barriers of our Active Targeting Liposome delivery platform to accelerate international multi-center clinical development and strive to bring breakthrough therapeutic solutions to patients worldwide as quickly as possible.”

Ning Gao, Partner and Head of Healthcare at Lake Bleu Capital, said: “Inno Medicine stands out as a highly differentiated and globally competitive company in the field of targeted nanomedicine delivery. We are particularly impressed by the Company’s long-term technological expertise and clinical translation capabilities in this field. We are delighted to lead this financing round and look forward to supporting Inno Medicine as it grows into a global leader in drug delivery.”

The Beijing Healthcare Industry Investment Fund and the Beijing Advanced Manufacturing and Intelligent Equipment Industry Investment Fund, both managed under Beijing State-owned Capital Operation and Management Co., Ltd. (Beijing State-Owned Capital), have invested in Inno Medicine. Representatives of the funds said: “This financing round is of significant importance to the development of Beijing’s biopharmaceutical innovation ecosystem and the broader national biopharmaceutical industry, and further demonstrates investors’ recognition of the value of Inno Medicine’s innovative drug delivery platform and core products. For the past decade, the Inno Medicine team has remained deeply committed to the development of innovative cardiovascular therapies, addressing significant unmet clinical needs worldwide and steadily advancing its core pipeline. We look forward to seeing Inno Medicine deliver a truly transformative cardiovascular therapy that can benefit patients at scale. We are highly confident in the Company’s value and global potential, and will provide our full support for its development in China and international expansion.”

A representative of Gaorong Ventures said: “Drug delivery technology is a critical breakthrough area for addressing key challenges in the development of complex therapeutics. Leveraging its proprietary Active Targeting Liposome (ATL) delivery platform, Inno Medicine has established strong technological barriers and a highly differentiated competitive advantage. We are impressed by the team’s outstanding execution capabilities and global perspective, and look forward to working together to accelerate the global development and commercialization of Inno Medicine’s innovative medicines.”

Dr. Shuai Li of Northern Light Venture Capital stated: “Inno Medicine has remained committed to original innovation for years, with its core pipelines addressing major global challenges in the treatment of atherosclerotic disease. We are delighted to continue our partnership with Inno Medicine and look forward to witnessing its original innovations from China reach patients around the world.”

About Inno Medicine

Founded in 2016, Beijing Inno Medicine Technology Co., Ltd. is an innovative biopharmaceutical company focused on the discovery, development, and commercialization of innovative, precision-targeted therapeutics. Driven by high-value unmet clinical needs worldwide, Inno Medicine leverages its proprietary Nano-Delivery Technology Platform to build a robust product pipeline spanning major disease areas, including cardiovascular diseases and neuro-oncology.

As a dedicated innovator in targeted nanomedicine delivery, Inno Medicine developed YN001—the world's first actively targeted candidate capable of reversing atherosclerotic plaque—which has successfully obtained dual IND approvals from both the U.S. FDA and National Medical Products Administration (NMPA) in China and is currently undergoing clinical trials. Moving forward, Inno Medicine continues to expand its globally proprietary pipeline to deliver precise, effective, and transformative treatment options to patients worldwide.